Abstract Body

High rates of syphilis and HIV infection among high-risk populations in the United States call for strategies to identify and treat new cases early. Dual rapid assays offer a convenient way to screen simultaneously for both infections, but to date there is no FDA-approved device. The INSTI Multiplex HIV-1/HIV-2/Syphilis Antibody Test (BioLytical, Richmond, BC, Canada) is a single use, rapid flow-through in vitro qualitative immunoassay detecting IgG antibodies to HIV-1(gp41), HIV-2(gp36) and Treponema pallidum(p17, p47) in whole/fingerstick blood, serum or plasma. Laboratory evaluations on serum have proven the device highly sensitive and specific for both infections. The field performance of the Multiplex was evaluated in a community clinical setting.

The study was conducted between August 2016 and September 2017 among adult patients visiting two outpatient clinics of the AIDS Healthcare Foundation in Los Angeles, California; the Healthcare Center serves patients with HIV infection, while the Wellness clinic offers HIV/STD testing. Fingerstick whole blood was tested on the Multiplex and it was compared to serum tested in the laboratory for HIV and TP antibodies. Participant’s infection status for HIV was determined using a 4th generation assay (Abbott Architect HIV Ag/Ab Combo, Abbott, IL). For syphilis, TP particle agglutination (Serodia TPPA, Fujirebio Inc, PA) with reflex to RPR and titer was performed. Sensitivity and specificity were calculated; sensitivity for syphilis is presented by RPR titer (Non-Reactive, 1:1-1:2, 1:4, ≥1:8). The exact binomial method was used to determine 95% confidence intervals (CI).

In total, 156 patients participated in the evaluation; 55 patients had detectable HIV antibodies, 51 had antibodies for TP and 39 had a reactive RPR. There were no invalid tests. Sensitivity for HIV antibodies was 98.2%(90.3%,99.9%) and specificity was 100%(96.4%,100%). Among TPPA confirmed specimens, sensitivity was 8.3%(0.2%,38.5%) in those with a Non-Reactive RPR, 40%(21.1%,61.3%) for RPR titers 1:1 and 1:2, 60%(14.7%,94.7%) for RPR titer 1:4 and 100%(66.4%,100%) for RPR titer ≥1:8. Specificity was 97.1% (91.8% – 99.4%).

The INSTI Multiplex showed excellent performance for detection of HIV antibodies. The test is more sensitive in specimens with higher RPR antibody titers, when recent or active infection is more likely. Further research is required to evaluate its role in screening programs.